3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Maʻemaʻe > 99.0% Lenalidomide Intermediate Factory
ʻO Ruifu Chemical ka mea hana nui o 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) me ke kūlana kiʻekiʻe, waena o Pomalidomide (CAS: 19171-19-8).Hiki iā Ruifu Chemical ke hāʻawi aku i ka honua holoʻokoʻa, ke kumukūʻai hoʻokūkū, ka lawelawe maikaʻi loa, ka liʻiliʻi a me ka nui nui i loaʻa.E kūʻai i ka 3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Inoa Kimia | 3-Aminopiperidine-2,6-Dione Hydrochloride |
| Nā huaʻōlelo like | 3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| Helu CAS | 24666-56-6 |
| CAS pili | 2686-86-4;25181-50-4 |
| Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
| ʻĀpana Molekala | C5H9ClN2O2 |
| Kaumaha Molecular | 164.59 |
| Lae hehee | 120 ℃ |
| COA & MSDS | Loaʻa |
| Ke kumu | Shanghai, Kina |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Pauda Crystalline Keʻokeʻo |
| Maʻemaʻe / Kaʻina Hanana | >99.0% (HPLC) |
| Māmā (KF) | <0.50% |
| Nalo ma ka maloo | <0.50% |
| Koena ma ka Ignition | <0.20% |
| Huina paumaele | <1.00% |
| Infrared Spectrum | Kūlike i ka hoʻolālā |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | Kūwaena o Lenalidomide (CAS: 191732-72-6) |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai
ʻO 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) he mea waena no ka hoʻomākaukau ʻana iā Lenalidomide (CAS: 191732-72-6).ʻO Lenalidomide kahi ʻano lāʻau antitumor i hoʻomohala ʻia e nā hui lāʻau olaola ʻAmelika.He nui nā hana e like me ka anti-tumor, ka hoʻoponopono immune a me ka anti-angiogenesis.Hiki iā ia ke kāohi i ka huna ʻana o nā cytokine inflammatory, a hoʻonui i ka huna ʻana o nā cytokines anti-inflammatory anti-inflammatory peripheral koko.Hiki iā ia ke keʻakeʻa i ka ulu ʻana o nā maʻi maʻi me ka nui o ka myeloma cell a me MM1S cell.Elua multicenter randomized double-blind placebo-controlled clinical studies loving the safety and curative effect of lenalidomide i hoʻohana ʻia no ka myeloma lehulehu.Hōʻike nā hopena noiʻi lāʻau hou ʻaʻole i loaʻa i ka lenalidomide ka hopena curative wale nō i ka mālama ʻana iā MDS a me MM, akā no ka mālama ʻana i ka myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis a me ka maʻi fibrosis iwi iwi me ka momona ʻaʻole.I Kekemapa 2005, ua ʻae ka US Food and Drug Administration (FDA) i ka lenalidomide e hoʻohana i ka mālama ʻana i ka myelodysplastic syndrome (MDS).
